Sandhya A. Shukla

Dr. Sandhya A. Shukla

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Onco
Verified
Journal Article
Open access
PDF file
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
NRNavin Ray
Navin Ray
Fowzul Islam FahadFowzul Islam Fahad
Fowzul Islam Fahad
RMRAJ MONGRE
RAJ MONGRE
Breast cancer is one of the most common and difficult-to-treat cancers affecting women globally. Long-term treatment success is still limited by problems like drug resistance, toxicity, and recurrence, even with advancements in conventional therapies. The application of substances derived from plants for medical purposes, or phytotherapy, has become a viable adjunctive approach to the treatment of breast cancer. An integrative approach to phytotherapy is examined in this review, focusing on how it can alter important molecular pathways implicated in the development, progression, and metastasis of breast cancer. By focusing on important signaling cascades like TGF-β, Wnt, Hedgehog, Notch, IL-6, Integrins, VEGF, HER2, EGFR, PI3K/Akt, and MAPK, and estrogen receptor pathways, a variety of phytochemicals, such as flavonoids, alkaloids, terpenoids, and polyphenols, demonstrate strong anticancer effects. This review also discusses how they affect immune modulation, angiogenesis, cell cycle regulation, and apoptosis. Moreover, it also emphasizes the challenges with these natural compounds’ bioavailability, standardization, and clinical translation while highlighting preclinical and clinical research that supports their therapeutic potential. This review attempts to give a thorough grasp of how plant-based compounds can support efficient and focused breast cancer treatments by fusing molecular insights with phytotherapeutic approaches.

21 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
SSSonali Pradeep Suryawanshi
Sonali Pradeep Suryawanshi
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
NRNavin Ray
Navin Ray
RMRAJ MONGRE
RAJ MONGRE
Recent advancements in three-dimensional (3D) bioprinting have revolutionized the modeling of skin cancer, enabling the fabrication of high-throughput, patient-specific organoids that recapitulate the structural, functional, and microenvironmental complexity of native tumors. This review focuses on the integration of cutting-edge bioprinting technologies with bioengineered extracellular matrices and patient-derived cells to generate physiologically relevant skin cancer models for diagnostic and personalized medicine applications. Key technological innovations, including novel bioinks, multi-material printing strategies, and biomimetic approaches, are discussed for their ability to replicate tumor-stroma interactions, vascularization, and immune microenvironments. The utility of bioprinted organoids in high-throughput drug screening, mutation-targeted therapy design, and biomarker discovery is critically evaluated. Additionally, we address current challenges in standardization, reproducibility, and clinical translation, highlighting regulatory and quality-control considerations. Collectively, this review emphasizes the transformative potential of 3D bioprinted skin cancer organoids as platforms for precision oncology, bridging bioengineering advances with translational research to accelerate therapeutic development and personalized treatment strategies.

9 May 2025 in Onco
Verified
Journal Article
Open access
PDF file
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
NRNavin Ray
Navin Ray
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
Fowzul Islam FahadFowzul Islam Fahad
Fowzul Islam Fahad
RMRAJ MONGRE
RAJ MONGRE
Globally, women’s cancer-related morbidity and death are still caused mainly by gynecologic cancer. Antioxidant and anti-inflammatory drugs have shown promise in treating gynecologic cancer because of the complex interactions among oxidative stress, inflammation, and the development of tumors. This review focuses on how these drugs, which include polyphenols, terpenoids, and thiols-related phytochemical-derived compounds target different pathways associated with developing and progressing gynecologic cancer. We investigate what factors affect the tumor microenvironment, specifically how they affect immunological response and vasculogenesis. Through the review of recent studies, we have gained an extensive understanding of the molecular pathways that anti-inflammatory and antioxidant drugs use to achieve their therapeutic benefits. Gynecologic cancer is still a potent cause of cancer-related deaths and fatalities for women globally. Antioxidant and anti-inflammatory drugs have shown promise in treating gynecologic cancer because of the complex interactions among oxidative stress, inflammation, and the development of tumors. This review focuses on how these drugs target different pathways associated with developing and progressing gynecologic cancer. We investigate what factors affect the tumor microenvironment, specifically how they affect immunological response and vasculogenesis. Through the review of recent studies, we have gained an extensive understanding of the molecular pathways that anti-inflammatory and antioxidant drugs use to achieve their therapeutic benefits.

5 November 2025 in Organoids
Verified
Journal Article
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
RMRAJ MONGRE
RAJ MONGRE
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
TGThiruppathi Govindhan
Thiruppathi Govindhan
Sayan Deb DuttaSayan Deb Dutta
Sayan Deb Dutta
Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.

5 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
ANARULKUMAR NAGAPPAN
ARULKUMAR NAGAPPAN
RMRAJ MONGRE
RAJ MONGRE
The integration of 3D bioprinting technology and CRISPR-Cas9 genome editing has become a game-changing method for creating complex organotypic cancer models. This integrated platform overcomes the drawbacks of traditional 2D culture systems by enabling precise genetic modifications within physiologically relevant, biomimetic tumor microenvironments. Researchers can more precisely recreate tumor progression, oncogenic mutations, cellular heterogeneity, and drug resistance mechanisms by utilizing the structural complexity provided by 3D bioprinting and the specificity of CRISPR-Cas9-mediated gene editing. CRISPR-Cas9 enables specific gene modifications, including oncogene knockout (e.g., MYC, KRAS) or immune checkpoint genes (e.g., PD-1, PD-L1), in 3D-bioprinted structures made from tumorigenic or patient-specific cell populations. It has been demonstrated that these modified models maintain important histopathological and molecular characteristics of original tumors, allowing for accurate high-throughput screening of immunotherapeutics and anticancer drugs. Significantly speeding up the modeling of tumorigenesis, studies using prostate cancer organoids showed gene correction efficiencies ranging from 50 to 90 %. Additionally, in 3D cultures, combinatorial CRISPR-Cas9 editing has demonstrated synergistic drug responses in models of lung and breast cancer, underscoring the platform's potential for discovering new therapeutic targets. Biomaterial-based vectors, like hydrogels and nanocarriers, are being improved to reduce off-target effects and increase intracellular uptake to increase the accuracy and safety of CRISPR delivery. However, issues with scalability, reproducibility, and standardization still exist, requiring ongoing interdisciplinary cooperation to improve downstream validation procedures, gene-editing tactics, and bioink formulations. The potential of CRISPR-Cas9-integrated 3D bioprinting as a state-of-the-art technique for drug discovery and cancer modeling is highlighted in this review. It emphasizes how the platform can speed up translational research in oncology, lessen dependency on animal models, and customize treatment plans. The goal of this review is to present a thorough summary of current developments, technical difficulties, and potential paths forward in this quickly developing field.

18 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
Sayan Deb DuttaSayan Deb Dutta
Sayan Deb Dutta
RMRAJ MONGRE
RAJ MONGRE
Skin cancer remains a major global health burden, necessitating more accurate models for understanding disease mechanisms, drug responses, and patient variability. Recent advancements in three-dimensional (3D) bioprinting have enabled the development of high-throughput, patient-specific organoids that closely mimic the structural and functional characteristics of native skin tumors. This review highlights the integration of 3D bioprinting technologies with bioengineered extracellular matrices and patient-derived cells to fabricate skin cancer organoids for diagnostic screening and personalized medicine applications. We discuss key bioinks, printing strategies, and biomimetic approaches used to replicate the tumor microenvironment, as well as the incorporation of immune and stromal components for enhanced physiological relevance. The utility of these organoids in high-throughput drug screening, mutation-specific therapy design, and biomarker discovery is also evaluated. Furthermore, we explore current challenges and future directions for translating bioprinted skin cancer models into clinical workflows. Collectively, this review underscores the transformative potential of 3D bioprinted organoids in the precision oncology landscape for skin cancer.